EVOTEC INTERNATIONAL GMBH

Their core work

Evotec International is the Hamburg-based arm of a major German drug discovery and development company, contributing preclinical and clinical development capabilities to European anti-infective research consortia. Their H2020 footprint is concentrated entirely on the antimicrobial resistance (AMR) challenge — specifically the discovery and advancement of new antibiotics against gram-negative pathogens and drug-resistant tuberculosis. They bring industrial-grade capabilities in drug discovery workflows, animal infection models, and clinical trial design to public-private consortia where academic partners typically handle early science. Their role is to help move candidate molecules from lab bench toward clinic-ready assets.

What they specialise in

How they've shifted over time

Their H2020 activity is tightly clustered in 2019-2020, so the visible arc is short rather than a multi-year shift. Early projects focus on gram-negative antibiotic candidates (GNA NOW, COMBINE), while the 2020 addition of ERA4TB extends their scope into tuberculosis regimen and preclinical development. The direction is a widening of AMR scope from single-pathogen antibacterial discovery toward multi-drug regimen and clinical-stage translation.

They are moving from single-compound antibacterial discovery toward full regimen and clinical-stage development, making them an increasingly attractive partner for consortia that need an industrial translation engine.

How they like to work

Evotec participates as an industrial partner inside coordinator-led consortia rather than steering projects themselves. With 52 distinct partners across just three projects, they operate inside very large public-private consortia typical of IMI-style AMR programs. Expect them to contribute defined drug-development work packages, not to run the scientific agenda.

They have collaborated with 52 distinct partners across 14 European countries through just three projects, reflecting the dense, pan-European consortia typical of IMI-backed antimicrobial research. Geographic reach is broadly European with a strong German anchor.

What sets them apart

Evotec is one of very few European industrial partners with the end-to-end capability to take an antibiotic candidate from preclinical profiling through clinical development — and they have committed this capability specifically to AMR, a commercially unattractive area most big pharma has exited. For a consortium that needs industrial drug-development muscle behind academic AMR science, they are an unusually well-matched partner. Their participation in all three flagship European AMR accelerators (GNA NOW, COMBINE, ERA4TB) makes them a de facto hub of the European antibiotic pipeline.

Highlights from their portfolio

• ERA4TB
  Flagship European tuberculosis regimen accelerator working on the PAN-TB combination regimen — one of the largest public-private TB drug development efforts in Europe.
• GNA NOW
  Dedicated industrial-academic push to deliver a new gram-negative antibiotic clinical candidate, addressing the WHO priority pathogen list.
• COMBINE
  Cross-cuts antibacterial discovery, animal models and clinical trial methodology for MDR infections — a broad methodological backbone project for European AMR research.